The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.

Oncogene
Nicolas SkrypekN Jonckheere

Abstract

The fluorinated analog of deoxycytidine, Gemcitabine (Gemzar), is the main chemotherapeutic drug in pancreatic cancer, but survival remains weak mainly because of the high resistance of tumors to the drug. Recent works have shown that the mucin MUC4 may confer an advantage to pancreatic tumor cells by modifying their susceptibility to drugs. However, the cellular mechanism(s) responsible for this MUC4-mediated resistance is unknown. The aim of this work was to identify the cellular mechanisms responsible for gemcitabine resistance linked to MUC4 expression. CAPAN-2 and CAPAN-1 adenocarcinomatous pancreatic cancer (PC) cell lines were used to establish stable MUC4-deficient clones (MUC4-KD) by shRNA interference. Measurement of the IC50 index using tetrazolium salt test indicated that MUC4-deficient cells were more sensitive to gemcitabine. This was correlated with increased Bax/BclXL ratio and apoptotic cell number. Expression of Equilibrative/Concentrative Nucleoside Transporter (hENT1, hCNT1/3), deoxycytidine kinase (dCK), ribonucleotide reductase (RRM1/2) and Multidrug-Resistance Protein (MRP3/4/5) was evaluated by quantitative RT-PCR (qRT-PCR) and western blotting. Alteration of MRP3, MRP4, hCNT1 and hCNT3 expression was ob...Continue Reading

References

Mar 25, 2000·Endocrine-related Cancer·S KrajewskiJ C Reed
Aug 5, 2000·International Journal of Cancer. Journal International Du Cancer·M KomatsuK L Carraway
Dec 7, 2000·Journal of the National Cancer Institute·K LeeG D Kruh
Jul 31, 2001·International Journal of Cancer. Journal International Du Cancer·T OguriN Kohno
Jul 2, 2002·American Journal of Clinical Pathology·Michael J SwartzPedram Argani
Oct 25, 2003·Oncogene·Gary D Kruh, Martin G Belinsky
Nov 16, 2004·Biochemical and Biophysical Research Communications·Maria van der SluisIsabelle Van Seuningen
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Jörg KönigDietrich Keppler
Sep 1, 2005·Pharmaceutical Research·Quan TianShufeng Zhou
Dec 3, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ashish V Kalra, Robert B Campbell
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raphaël MaréchalJean-Luc Van Laethem
Jul 23, 2009·Biochemical Pharmacology·Dirk TheileJohanna Weiss
Sep 10, 2009·British Journal of Cancer·S BafnaS K Batra
Sep 9, 2010·Neoplasia : an International Journal for Oncology Research·Wolfgang HagmannJohannes Matthias Löhr
Dec 18, 2010·The Lancet Oncology·Lars Petter JordheimCharles Dumontet
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
May 31, 2011·Lancet·Audrey VincentMichael Goggins
Jan 1, 2010·Cancers·Nicolas JonckheereIsabelle Van Seuningen

❮ Previous
Next ❯

Citations

Nov 19, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Nicolas Jonckheere, Isabelle Van Seuningen
Jun 4, 2015·Biochimica Et Biophysica Acta·Solange TréhouxIsabelle Van Seuningen
May 3, 2014·Biochimica Et Biophysica Acta·Nicolas JonckheereIsabelle Van Seuningen
Aug 2, 2014·European Journal of Pharmacology·Lucas de Sousa Cavalcante, Gisele Monteiro
May 31, 2016·Neoplasia : an International Journal for Oncology Research·Yunus Emre TarhanJae-Hyun Park
Dec 17, 2014·Biochemical and Biophysical Research Communications·Solange TréhouxIsabelle Van Seuningen
Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jungwhoi LeeJae Hoon Kim
Jun 12, 2016·Journal of Experimental & Clinical Cancer Research : CR·Jie TangZekuan Xu
May 22, 2016·Molecular Carcinogenesis·Jingjing GongAddanki P Kumar
May 4, 2017·Expert Opinion on Therapeutic Targets·Shailendra K GautamManeesh Jain
Sep 10, 2015·Biological Chemistry·Michael Jaehme, Dirk Jan Slotboom
Sep 14, 2019·Brazilian Journal of Microbiology : [publication of the Brazilian Society for Microbiology]·Lucas de Sousa CavalcanteGisele Monteiro
Sep 14, 2019·International Journal of Molecular Sciences·Siyuan ZengHai Yang
Jun 13, 2019·Annals of Surgical Oncology·Marian KhaliliWilbur B Bowne
Feb 8, 2020·Clinical and Experimental Pharmacology & Physiology·Meixiong Cheng, Ling Liu
Mar 25, 2020·Oncotarget·Emanuela Dell'AquilaDaniele Santini
May 28, 2020·European Journal of Cancer Care·Sina AbdkarimiBehzad Baradaran
Mar 18, 2016·International Journal of Oncology·Enrique P GarcíaTeresa Freire

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.